A phase 2, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox–Gastaut syndrome (ELEKTRA)

OBJECTIVE: Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS) are rare treatment‐resistant childhood epilepsies classed as developmental and epileptic encephalopathies. ELEKTRA investigated the efficacy and safety of soticlestat (TAK‐935) as adjunctive therapy in children with DS or LGS (NCT0365...

Descripción completa

Detalles Bibliográficos
Autores principales: Hahn, Cecil D., Jiang, Yuwu, Villanueva, Vicente, Zolnowska, Marta, Arkilo, Dimitrios, Hsiao, Samuel, Asgharnejad, Mahnaz, Dlugos, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804149/
https://www.ncbi.nlm.nih.gov/pubmed/35841234
http://dx.doi.org/10.1111/epi.17367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804149/
https://www.ncbi.nlm.nih.gov/pubmed/35841234
http://dx.doi.org/10.1111/epi.17367

Ejemplares similares